The impact of anti-TNF treatment on Wnt signaling, noggin, and cytokine levels in axial spondyloarthritis.
Anti-TNF treatment
Axial spondyloarthritis
IL-17
Noggin
Wnt signaling
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
04
06
2021
accepted:
16
01
2022
revised:
20
12
2021
pubmed:
22
1
2022
medline:
4
5
2022
entrez:
21
1
2022
Statut:
ppublish
Résumé
Anti-tumor necrosis factor (anti-TNF) agents are commonly used in treatment of axial spondyloarthritis (axSpA), but clinical and radiological improvement is not achieved in all patients. We aimed to investigate the impact of anti-TNFs on inflammatory and noninflammatory parameters in patients with axSpA. In this longitudinal study, 30 biologic naïve axSpA patients with high disease activity and 30 healthy controls were enrolled. All patients were treated with anti-TNF agents for 6 months. ASDAS-CRP, BASDAI, BASFI, BASMI, patient and physician global assessments were evaluated. C-reactive protein, COX2, TNF-α IL-6, IL-17, IL-22, IL-23, IL-33, sclerostin, dickkopf-1, and noggin levels were evaluated at baseline and at 6 months of anti-TNF treatment. At baseline, axSpA patients had significantly higher median (IQR) TNF-α levels, 34.4 (31.4-37.03) vs. 18.1 (12.1-28.4) pg/ml (p < 0.001), and lower DKK1, 446.7 (356.9-529.3) vs. 1088.7 (951.7-1244.4) pg/ml, and sclerostin, 312.4 (140.8-412.7) vs. 412.3 (295.4-512.8) pg/ml, compared to healthy controls (all p < 0.001). The median (IQR) serum levels of IL-17, IL-22, and IL-33 increased significantly after 6 months of anti-TNF treatment, from 93.3 (85.1-104.8) to 102.1 (86.6-114.6) pg/ml (p = 0.026), 159.2 (151.9-178.4) to 183.5 (156.3-304.6) pg/ml (p = 0.033), and 127.8 (106.6-186.1) to 147.06 (128.5-213.4) pg/ml (p = 0.016), respectively. Sclerostin and DKK-1 levels increased significantly after anti-TNF treatment from 312.4 (140.8-412.7) to 405.1 (276.3-452.5) pg/ml (p = 0.018) and 446.7 (356.9-529.3) to 881.3 (663.1-972.2) pg/ml (p < 0.001), while there was no significant change in noggin level. Many inflammatory cytokines increase after anti-TNF treatment and noggin is not affected by anti-TNF treatment in AxSpA. Noggin might be a therapeutic target in patients with axSpA. • Anti-TNF therapy is not sufficient for complete blockage of the inflammatory process in axial spondyloarthritis. • The increase in IL-17, IL-22, and IL-33 may decrease the efficiency of anti-TNF therapy. • Noggin might be a therapeutic target as a complementary or alternative approach to anti-TNF therapy in axial spondyloarthritis.
Identifiants
pubmed: 35059881
doi: 10.1007/s10067-022-06070-w
pii: 10.1007/s10067-022-06070-w
doi:
Substances chimiques
Cytokines
0
Interleukin-17
0
Interleukin-33
0
Tumor Necrosis Factor Inhibitors
0
Tumor Necrosis Factor-alpha
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1381-1389Subventions
Organisme : Gazi Üniversitesi
ID : 01/2019-34.
Informations de copyright
© 2022. International League of Associations for Rheumatology (ILAR).
Références
Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390(10089):73–84. https://doi.org/10.1016/S0140-6736(16)31591-4
doi: 10.1016/S0140-6736(16)31591-4
pubmed: 28110981
Schett G, Rudwaleit M (2010) Can we stop progression of ankylosing spondylitis? Best Pract Res Clin Rheumatol 24(3):363–371. https://doi.org/10.1016/j.berh.2010.01.005
doi: 10.1016/j.berh.2010.01.005
pubmed: 20534370
van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978–991. https://doi.org/10.1136/annrheumdis-2016-210770
doi: 10.1136/annrheumdis-2016-210770
pubmed: 28087505
Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187–1193. https://doi.org/10.1016/s0140-6736(02)08215-6
doi: 10.1016/s0140-6736(02)08215-6
pubmed: 11955536
van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136–2146. https://doi.org/10.1002/art.21913
doi: 10.1002/art.21913
pubmed: 16802350
Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS et al (2016) American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 68(2):282–298. https://doi.org/10.1002/art.39298
doi: 10.1002/art.39298
pubmed: 26401991
Simone D, Al Mossawi MH, Bowness P (2018) Progress in our understanding of the pathogenesis of ankylosing spondylitis. Rheumatology (Oxford) 57(suppl_6):vi4–vi9. https://doi.org/10.1093/rheumatology/key001
doi: 10.1093/rheumatology/key001
Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J et al (2012) IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 18(7):1069–1076. https://doi.org/10.1038/nm.2817
doi: 10.1038/nm.2817
pubmed: 22772566
McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM et al (2009) The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 10(3):314–324. https://doi.org/10.1038/ni.1698
doi: 10.1038/ni.1698
pubmed: 19182808
pmcid: 2945605
Inman RD, Baraliakos X, Hermann KA, Braun J, Deodhar A, van der Heijde D et al (2016) Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study. Arthritis Res Ther 18(1):304. https://doi.org/10.1186/s13075-016-1200-1
doi: 10.1186/s13075-016-1200-1
pubmed: 28031053
pmcid: 5192572
Li GX, Wang S, Duan ZH, Zeng Z, Pan FM (2013) Serum levels of IL-33 and its receptor ST2 are elevated in patients with ankylosing spondylitis. Scand J Rheumatol 42(3):226–231. https://doi.org/10.3109/03009742.2012.735700
doi: 10.3109/03009742.2012.735700
pubmed: 23409750
Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H et al (2012) High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 71(4):572–574. https://doi.org/10.1136/annrheumdis-2011-200216
doi: 10.1136/annrheumdis-2011-200216
pubmed: 22186710
Saad CG, Ribeiro AC, Moraes JC, Takayama L, Goncalves CR, Rodrigues MB et al (2012) Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther 14(5):R216. https://doi.org/10.1186/ar4055
doi: 10.1186/ar4055
pubmed: 23062122
pmcid: 3580528
Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY et al (2012) Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int 32(8):2523–2527. https://doi.org/10.1007/s00296-011-1981-0
doi: 10.1007/s00296-011-1981-0
pubmed: 21833531
Thomas JT, Lin K, Nandedkar M, Camargo M, Cervenka J, Luyten FP (1996) A human chondrodysplasia due to a mutation in a TGF-beta superfamily member. Nat Genet 12(3):315–317. https://doi.org/10.1038/ng0396-315
doi: 10.1038/ng0396-315
pubmed: 8589725
Polinkovsky A, Robin NH, Thomas JT, Irons M, Lynn A, Goodman FR et al (1997) Mutations in CDMP1 cause autosomal dominant brachydactyly type C. Nat Genet 17(1):18–19. https://doi.org/10.1038/ng0997-18
doi: 10.1038/ng0997-18
pubmed: 9288091
Olsen BR, Reginato AM, Wang W (2000) Bone development. Annu Rev Cell Dev Biol 16:191–220. https://doi.org/10.1146/annurev.cellbio.16.1.191
doi: 10.1146/annurev.cellbio.16.1.191
pubmed: 11031235
Waite KA, Eng C (2003) From developmental disorder to heritable cancer: it’s all in the BMP/TGF-beta family. Nat Rev Genet 4(10):763–773. https://doi.org/10.1038/nrg1178
doi: 10.1038/nrg1178
pubmed: 14526373
Massague J (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1(3):169–178. https://doi.org/10.1038/35043051
doi: 10.1038/35043051
pubmed: 11252892
Fan J, Im CS, Guo M, Cui ZK, Fartash A, Kim S et al (2016) Enhanced osteogenesis of adipose-derived stem cells by regulating bone morphogenetic protein signaling antagonists and agonists. Stem Cells Transl Med 5(4):539–551. https://doi.org/10.5966/sctm.2015-0249
doi: 10.5966/sctm.2015-0249
pubmed: 26956209
pmcid: 4798741
Wan DC, Pomerantz JH, Brunet LJ, Kim JB, Chou YF, Wu BM et al (2007) Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation. J Biol Chem 282(36):26450–26459. https://doi.org/10.1074/jbc.M703282200
doi: 10.1074/jbc.M703282200
pubmed: 17609215
Lories RJ, Derese I, Luyten FP (2005) Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 115(6):1571–1579. https://doi.org/10.1172/JCI23738
doi: 10.1172/JCI23738
pubmed: 15902307
pmcid: 1090472
Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M et al (2010) Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 62(1):150–158. https://doi.org/10.1002/art.27231
doi: 10.1002/art.27231
pubmed: 20039407
Korkosz M, Gasowski J, Leszczynski P, Pawlak-Bus K, Jeka S, Siedlar M et al (2014) Effect of tumour necrosis factor-alpha inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity. Scand J Rheumatol 43(1):43–48. https://doi.org/10.3109/03009742.2013.805241
doi: 10.3109/03009742.2013.805241
pubmed: 24447112
Machado MA, Barbosa MM, Almeida AM, de Araujo VE, Kakehasi AM, Andrade EI et al (2013) Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int 33(9):2199–2213. https://doi.org/10.1007/s00296-013-2772-6
doi: 10.1007/s00296-013-2772-6
pubmed: 23686218
Baraliakos X, Davis J, Tsuji W, Braun J (2005) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 52(4):1216–1223. https://doi.org/10.1002/art.20977
doi: 10.1002/art.20977
pubmed: 15818694
Lambert RG, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG et al (2007) Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 56(12):4005–4014. https://doi.org/10.1002/art.23044
doi: 10.1002/art.23044
pubmed: 18050198
van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P et al (2008) Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58(10):3063–3070. https://doi.org/10.1002/art.23901
doi: 10.1002/art.23901
pubmed: 18821688
Baraliakos X, Haibel H, Listing J, Sieper J, Braun J (2014) Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 73(4):710–715. https://doi.org/10.1136/annrheumdis-2012-202698
doi: 10.1136/annrheumdis-2012-202698
pubmed: 23505240
Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S et al (2012) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 71(5):661–667. https://doi.org/10.1136/ard.2011.154799
doi: 10.1136/ard.2011.154799
pubmed: 22012970
Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25–31. https://doi.org/10.1136/ard.2010.133645
doi: 10.1136/ard.2010.133645
pubmed: 21109520
van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368. https://doi.org/10.1002/art.1780270401
doi: 10.1002/art.1780270401
pubmed: 6231933
Milanez FM, Saad CG, Viana VT, Moraes JC, Perico GV, Sampaio-Barros PD et al (2016) IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients. Arthritis Res Ther 18:52. https://doi.org/10.1186/s13075-016-0949-6
doi: 10.1186/s13075-016-0949-6
pubmed: 26912133
pmcid: 4765065
Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J et al (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 46(9):1450–1453. https://doi.org/10.1093/rheumatology/kem166
doi: 10.1093/rheumatology/kem166
Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I et al (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52(6):1756–1765. https://doi.org/10.1002/art.21054
doi: 10.1002/art.21054
pubmed: 15934081
Kroon F, Landewe R, Dougados M, van der Heijde D (2012) Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 71(10):1623–1629. https://doi.org/10.1136/annrheumdis-2012-201370
doi: 10.1136/annrheumdis-2012-201370
pubmed: 22532639
Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J et al (2016) Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 75(8):1438–1443. https://doi.org/10.1136/annrheumdis-2015-207897
doi: 10.1136/annrheumdis-2015-207897
pubmed: 26242443
Park JY, Pillinger MH, Abramson SB (2006) Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 119(3):229–240. https://doi.org/10.1016/j.clim.2006.01.016
doi: 10.1016/j.clim.2006.01.016
pubmed: 16540375
Proft F, Muche B, Listing J, Rios-Rodriguez V, Sieper J, Poddubnyy D (2017) Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) - an open-label randomized controlled multicenter trial. BMJ Open 7(6):e014591. https://doi.org/10.1136/bmjopen-2016-014591
doi: 10.1136/bmjopen-2016-014591
pubmed: 28601821
pmcid: 5623356
Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116(5):1202–1209. https://doi.org/10.1172/JCI28551
doi: 10.1172/JCI28551
pubmed: 16670761
pmcid: 1451219
Delgado-Calle J, Sato AY, Bellido T (2017) Role and mechanism of action of sclerostin in bone. Bone 96:29–37. https://doi.org/10.1016/j.bone.2016.10.007
doi: 10.1016/j.bone.2016.10.007
pubmed: 27742498
Perrotta FM, Ceccarelli F, Barbati C, Colasanti T, De Socio A, Scriffignano S et al (2018) Serum sclerostin as a possible biomarker in ankylosing spondylitis: a case-control study. J Immunol Res 2018:9101964. https://doi.org/10.1155/2018/9101964
doi: 10.1155/2018/9101964
pubmed: 29854850
pmcid: 5954944
Xie W, Zhou L, Li S, Hui T, Chen D (2016) Wnt/beta-catenin signaling plays a key role in the development of spondyloarthritis. Ann N Y Acad Sci 1364:25–31. https://doi.org/10.1111/nyas.12968
doi: 10.1111/nyas.12968
pubmed: 26629686
Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156–163. https://doi.org/10.1038/nm1538
doi: 10.1038/nm1538
pubmed: 17237793
Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards W et al (2010) Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 69(3):592–597. https://doi.org/10.1136/ard.2008.102046
doi: 10.1136/ard.2008.102046
pubmed: 19304568
Gulyas K, Horvath A, Vegh E, Pusztai A, Szentpetery A, Petho Z et al (2020) Effects of 1-year anti-TNF-alpha therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 39(1):167–175. https://doi.org/10.1007/s10067-019-04771-3
doi: 10.1007/s10067-019-04771-3
pubmed: 31522318
Biver E, Hardouin P, Caverzasio J (2013) The “bone morphogenic proteins” pathways in bone and joint diseases: translational perspectives from physiopathology to therapeutic targets. Cytokine Growth Factor Rev 24(1):69–81. https://doi.org/10.1016/j.cytogfr.2012.06.003
doi: 10.1016/j.cytogfr.2012.06.003
pubmed: 22749766
Vukicevic S, Luyten FP, Reddi AH (1989) Stimulation of the expression of osteogenic and chondrogenic phenotypes in vitro by osteogenin. Proc Natl Acad Sci U S A 86(22):8793–8797. https://doi.org/10.1073/pnas.86.22.8793
doi: 10.1073/pnas.86.22.8793
pubmed: 2554330
pmcid: 298376
Yamaguchi A, Katagiri T, Ikeda T, Wozney JM, Rosen V, Wang EA et al (1991) Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol 113(3):681–687. https://doi.org/10.1083/jcb.113.3.681
doi: 10.1083/jcb.113.3.681
pubmed: 1849907
Harris SE, Sabatini M, Harris MA, Feng JQ, Wozney J, Mundy GR (1994) Expression of bone morphogenetic protein messenger RNA in prolonged cultures of fetal rat calvarial cells. J Bone Miner Res 9(3):389–394. https://doi.org/10.1002/jbmr.5650090314
doi: 10.1002/jbmr.5650090314
pubmed: 8191933
Hughes FJ, Collyer J, Stanfield M, Goodman SA (1995) The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells in vitro. Endocrinology 136(6):2671–2677. https://doi.org/10.1210/endo.136.6.7750491
doi: 10.1210/endo.136.6.7750491
pubmed: 7750491
Wang EA, Israel DI, Kelly S, Luxenberg DP (1993) Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors 9(1):57–71. https://doi.org/10.3109/08977199308991582
doi: 10.3109/08977199308991582
pubmed: 8347351
Leclerc C, Duprat AM, Moreau M (1999) Noggin upregulates Fos expression by a calcium-mediated pathway in amphibian embryos. Dev Growth Differ 41(2):227–238. https://doi.org/10.1046/j.1440-169x.1999.00421.x
doi: 10.1046/j.1440-169x.1999.00421.x
pubmed: 10223719
Gazzerro E, Gangji V, Canalis E (1998) Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J Clin Invest 102(12):2106–2114. https://doi.org/10.1172/JCI3459
doi: 10.1172/JCI3459
pubmed: 9854046
pmcid: 509165
Xie Z, Wang P, Li Y, Deng W, Zhang X, Su H et al (2016) Imbalance between bone morphogenetic protein 2 and noggin induces abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis. Arthritis Rheumatol 68(2):430–440. https://doi.org/10.1002/art.39433
doi: 10.1002/art.39433
pubmed: 26413886
Tsui FW, Tsui HW, Las Heras F, Pritzker KP, Inman RD (2014) Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis 73(10):1873–1879. https://doi.org/10.1136/annrheumdis-2013-203630
doi: 10.1136/annrheumdis-2013-203630
pubmed: 23894062
van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L et al (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58(5):1324–1331. https://doi.org/10.1002/art.23471
doi: 10.1002/art.23471
pubmed: 18438853
van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H et al (2009) Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 11(4):R127. https://doi.org/10.1186/ar2794
doi: 10.1186/ar2794
pubmed: 19703304
pmcid: 2745811
Maas F, Arends S, Brouwer E, Essers I, van der Veer E, Efde M et al (2017) Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors. Arthritis Care Res (Hoboken) 69(7):1011–1019. https://doi.org/10.1002/acr.23097
doi: 10.1002/acr.23097
van der Heijde D, Baraliakos X, Hermann KA, Landewe RBM, Machado PM, Maksymowych WP et al (2018) Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis 77(5):699–705. https://doi.org/10.1136/annrheumdis-2017-212377
doi: 10.1136/annrheumdis-2017-212377
pubmed: 29343510
Lories RJ, Luyten FP, de Vlam K (2009) Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther 11(2):221. https://doi.org/10.1186/ar2642
doi: 10.1186/ar2642
pubmed: 19439035
pmcid: 2688182
Hannallah D, Peng H, Young B, Usas A, Gearhart B, Huard J (2004) Retroviral delivery of Noggin inhibits the formation of heterotopic ossification induced by BMP-4, demineralized bone matrix, and trauma in an animal model. J Bone Joint Surg Am 86(1):80–91. https://doi.org/10.2106/00004623-200401000-00013
doi: 10.2106/00004623-200401000-00013
pubmed: 14711949
Aspenberg P, Jeppsson C, Economides AN (2001) The bone morphogenetic proteins antagonist Noggin inhibits membranous ossification. J Bone Miner Res 16(3):497–500. https://doi.org/10.1359/jbmr.2001.16.3.497
doi: 10.1359/jbmr.2001.16.3.497
pubmed: 11277267
Ghadakzadeh S, Hamdy RC, Tabrizian M (2017) Efficient in vitro delivery of Noggin siRNA enhances osteoblastogenesis. Heliyon 3(11):e00450. https://doi.org/10.1016/j.heliyon.2017.e00450
doi: 10.1016/j.heliyon.2017.e00450
pubmed: 29167826
pmcid: 5686427
Lim DH, Lee EJ, Kwon OC, Hong S, Lee CK, Yoo B et al (2019) Effect of tumor necrosis factor inhibition on spinal inflammation and spinal ankylosis in SKG mice. Sci Rep 9(1):18000. https://doi.org/10.1038/s41598-019-54549-5
doi: 10.1038/s41598-019-54549-5
pubmed: 31784598
pmcid: 6884438
Gravallese EM, Schett G (2018) Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol 14(11):631–640. https://doi.org/10.1038/s41584-018-0091-8
doi: 10.1038/s41584-018-0091-8
pubmed: 30266977
Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG et al (2013) The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 133(1):17–26. https://doi.org/10.1038/jid.2012.194
doi: 10.1038/jid.2012.194
pubmed: 22673731
Ogawa E, Sato Y, Minagawa A, Okuyama R (2018) Pathogenesis of psoriasis and development of treatment. J Dermatol 45(3):264–272. https://doi.org/10.1111/1346-8138.14139
doi: 10.1111/1346-8138.14139
pubmed: 29226422